Charles Rodney Greenaway Evans

This inventor holds 18 USPTO granted patents and 7 published patent applications, plus 3 CIPO patents and 3 EPO patents, primarily in Pharmaceutical Formulations. Top assignees: Aclaris Therapeutics, Inc., Palvella Therapeutics, Inc., Pellepharm, Inc.. Active years: 2017-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Charles Rodney Greenaway Evans. Retrieved from https://idiyas.com/inventor/charles-rodney-greenaway-evans

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 7)

% Patents Active = 72.2

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 5.1

ph-index = 3

Forward Citations = 28(Granted Patents)

Location History:

Surrey, GB (2017 - 2020)
Mitcham, GB (2020 - 2023)
Worthing, GB (2019 - 2024)

Company Filing History:

6 out of 21

Aclaris Therapeutics, Inc.

patents

6 out of 9

Palvella Therapeutics, Inc.

Timber Pharmaceuticals LLC

patents

5. 1 out of 1

Lipidio Pharmaceuticals Inc.

patent

Years Active: 2017-2025

Loading Chart...

Areas of Expertise:

mTOR Inhibitors

Isotretinoin Formulations

Hedgehog Inhibitors

Topical Formulations

Anhydrous Compositions

Non-Alcoholic Steatohepatitis

Peroxide Formulations

Patient Treatment Methods

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12329748 - Anhydrous compositions of mTOR inhibitors and methods of use (2025-06-17),

2. 12268673 - Anhydrous compositions of mTOR inhibitors and methods of use (2025-04-08),

3. 11865113 - Methods of treating a patient afflicted with non-alcoholic steatohepatitis (NASH) (2024-01-09),

4. 11679101 - Anhydrous compositions of mTOR inhibitors and methods of use (2023-06-20),

5. 11471408 - Isotretinoin formulations and uses and methods thereof (2022-10-18),

6. 11413283 - Topical formulations for delivery of hedgehog inhibitor compounds and use thereof (2022-08-16),

7. 11135204 - Anhydrous compositions of mTOR inhibitors and methods of use (2021-10-05),

8. 11000513 - Anhydrous compositions of mTOR inhibitors and methods of use (2021-05-11),

9. 10933018 - Isotretinoin formulations and uses and methods thereof (2021-03-02),

10. 10729720 - Peroxide formulations and methods and applicators for using the same (2020-08-04),

11. 10722499 - Anyhydrous compositions of mTOR inhibitors and methods of use (2020-07-28),

12. 10695344 - Topical formulations for delivery of hedgehog inhibitor compounds and use thereof (2020-06-30),

13. 10653721 - Peroxide formulations and methods and applicators for using the same (2020-05-19),

14. 10493103 - Peroxide formulations and methods and applicators for using the same (2019-12-03),

15. 10369147 - Topical formulations for delivery of hedgehog inhibitor compounds and use thereof (2019-08-06),

Title: Charles Rodney Greenaway Evans: Innovating Solutions for Skin Disorders

Introduction:

Charles Rodney Greenaway Evans is a highly accomplished inventor and researcher specializing in the development of pharmaceutical compositions for the treatment of various skin disorders. With a wealth of experience and expertise, Mr. Evans has contributed significantly to the field of dermatology through his innovative patented formulations. Let us delve into his recent patents, career highlights, collaborations, and lasting impact on the pharmaceutical industry.

Latest Patents:

Mr. Evans has made notable advancements in the topical delivery of mTOR inhibitors, as depicted in his patent titled "Anhydrous compositions of mTOR inhibitors and methods of use". This patent reveals unique compositions that include mTOR inhibitors, solvents, gelling agents, and antioxidants. These formulations offer effective treatment options for various skin disorders, utilizing novel methods of topical delivery.

Additionally, he has also developed groundbreaking isotretinoin formulations in his patent titled "Isotretinoin formulations and uses and methods thereof". These formulations provide enhanced dermal delivery for isotretinoin, utilizing a reduced level of ethanol, thereby improving its thermodynamic properties. This patent focuses on the treatment of conditions such as ichthyosis and other skin-related ailments.

Career Highlights:

Charles Rodney Greenaway Evans has worked with esteemed pharmaceutical companies such as Aclaris Therapeutics, Inc. and Palvella Therapeutics, Inc. during the course of his career. His expertise in the field of dermatology and pharmaceutical research has played a vital role in developing novel treatment options for various skin disorders.

Collaborations:

During his professional journey, Mr. Evans has collaborated with industry-leading experts, including Marc Barry Brown and Stuart D Shanler. These collaborations have fostered an environment of knowledge exchange and innovative thinking, leading to the development of groundbreaking patented formulations.

Conclusion:

Charles Rodney Greenaway Evans's contributions to the field of dermatology and pharmaceutical research are evident through his numerous patents and career highlights. Through his efforts, he has significantly advanced the treatment options available for individuals suffering from various skin disorders. His innovative formulations have paved the way for more effective and targeted therapies, improving the lives of many patients worldwide.

For more information on Charles Rodney Greenway Evans and other notable inventors and innovators, visit our website, idiyas.com, dedicated to exploring and celebrating the world of innovations and patents.

Profile summary based on public USPTO records.